Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15694MR)

This product GTTS-WQ15694MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15694MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14015MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ14516MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ7685MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ9432MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ3230MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ5530MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ7701MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4796MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT 5/9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.